Nanobody treatment to block MSUT2 and reduce harmful tau in Alzheimer's
Developing MSUT2 Nanobodies for Targeting Pathological Tau in Alzheimer's Disease
Tiny antibody-like treatments called nanobodies will be developed to block a protein (MSUT2) that helps harmful tau damage brain cells in people with Alzheimer's disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | VA Puget Sound Healthcare System NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11264893 on NIH RePORTER |
What this research studies
Researchers are making small, brain-penetrant antibody-like proteins (nanobodies) that stop MSUT2 from binding RNA, because MSUT2 activity makes neurons more vulnerable to tau-related damage. They will optimize these nanobodies and delivery methods and test them in laboratory and animal models that mimic human Alzheimer's to see if blocking MSUT2 can reverse tau-driven neurodegeneration after it starts. The team will use these tools to learn when and how MSUT2 makes tau more toxic and to produce lead biologic agents for future translation. The work is based at VA Puget Sound and is intended to set the stage for later human testing if results are promising.
Who could benefit from this research
Good fit: Adults with Alzheimer's disease or related tauopathies, especially those with evidence of tau accumulation and in early-to-moderate stages, would be the likely candidates for future trials.
Not a fit: People whose dementia is caused by non-tau diseases or who have very advanced, widespread brain damage may not benefit from this approach.
Why it matters
Potential benefit: If successful, this could lead to new treatments that reduce tau-related brain damage and slow memory and thinking decline in people with Alzheimer's.
How similar studies have performed: Existing antibody and gene approaches targeting tau have had mixed outcomes, and targeting MSUT2 with nanobodies is a novel approach not yet tested in people.
Where this research is happening
Seattle, United States
- VA Puget Sound Healthcare System — Seattle, United States (Active)
Researchers
- Principal investigator: Kraemer, Brian C. — VA Puget Sound Healthcare System
- Study coordinator: Kraemer, Brian C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.